C5241

Cinnamycin

from Streptomyces cinnamoneus, ≥95% (HPLC)

• 同義詞: Ro 09-0198
• 經驗公式（希爾表示法）: C₈₉H₁₂₅N₂₅O₂₅S₃
• CAS號碼: 110655-58-8
• 分子量：: 2041.29
• MDL號碼: MFCD01770867
• 分類程式碼代碼: 51111800
• NACRES: NA.77

屬性

• 生物源: Streptomyces cinnamoneus
• 品質等級: 200
• 化驗: ≥95% (HPLC)
• 形狀: solid
• 溶解度: DMSO: 10 mg/mL; acetonitrile: water (1:1): 5 mg/mL (requires heating)
• 抗生素活性譜: fungi
• 作用方式: cell membrane | interferes
• 儲存溫度: 2-8°C
• SMILES 字串: S1[C@@H](C2NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H]3NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]5NC(=O)[C@@H](NC(=O)[C@H]7N(CCC7)C(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C1)N)CCCN\C(=N/[H])\N)CCC(=O)N)CS
• InChI: 1S/C89H125N25O25S3/c1-43(2)66-84(133)109-59-41-140-40-58-79(128)108-60-42-142-45(4)68(86(135)105-55(75(124)110-66)34-48-22-12-7-13-23-48)111-76(125)54(33-47-20-10-6-11-21-47)104-82(131)61-26-17-31-114(61)65(118)38-98-72(121)53(32-46-18-8-5-9-19-46)103-78(127)57(106-80(60)129)36-95-29-15-14-24-52(87(136)137)102-85(134)67(112-77(126)56(35-63(92)116)99-64(117)37-97-83(132)69(113-81(59)130)70(119)88(138)139)44(3)141-39-49(90)71(120)100-50(25-16-30-96-89(93)94)73(122)101-51(74(123)107-58)27-28-62(91)115/h5-13,18-23,43-45,49-61,66-70,95,119H,14-17,24-42,90H2,1-4H3,(H2,91,115)(H2,92,116)(H,97,132)(H,98,121)(H,99,117)(H,100,120)(H,101,122)(H,102,134)(H,103,127)(H,104,131)(H,105,135)(H,106,129)(H,107,123)(H,108,128)(H,109,133)(H,110,124)(H,111,125)(H,112,126)(H,113,130)(H,136,137)(H,138,139)(H4,93,94,96)/t44-,45?,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,66+,67?,68+,69+,70-/m1/s1
• InChI 密鑰: QJDWKBINWOWJNZ-IDGBIKHQSA-N

描述

Amino Acid Sequence

Cys-Arg-Gln-Cys-Cys--3-NH₂-Ala-Phe-Gly-Pro-Phe-(2S,3S)-2-amino-3-mercaptobutanoyl-Phe-Val-Cys-3-OH-α-Asp-Gly-Asn-(2S,3S)-2-amino-3-mercaptobutanoyl-Lys Disulfide bridges: 1-18, 4-14, 5-11; Lysinoalanine bridge: 6-19

一般說明

Cinnamycin is synthesized after proteolytic cleavage from core peptide and takes up a compact globular structure.[1]

應用

Cinnamycin has been used in cinnamycin senstivity assay in mouse embryonic fibroblasts (MEFs).[2]

生化／生理作用

Cinnamycin based analogs may be useful in treating cystic fibrosis or Clostridium infections.[1]

Cinnamycin is a tetracyclic polypeptide antibiotic containing 19 amino acids. The polypeptide has the unusual amino acids threo-3-methyl-lanthionine, meso-lanthionine, lysinoalanine and 3-hydroxyaspartic acid. It is produced by Streptomyces cinnamoneus and belongs to the duramycin-type l antibiotics. Lantibiotics are synthesized in the ribosome and undergo extensive post-translational modifications to attain their active antimicrobial form. The unique receptor for Cinnamycin, phosphatidylethanolamine (PE), is located on the inner leaflet of the plasma membrane. Cinnamycin induces transbilayer lipid movement leading to the exposure of PE to the outer leaflet of the plasma membrane. The interaction of Cinnamycin with PE provides a tool for PE monitoring. Cinnamycin is active against Gram-positive rods such as Bacilli, Clostyridium and Mycobacterium, causing cell wall biosynthesis stress.
Cinnamycin, like other lantibiotics, was also reported to inhibit phospholipase A2 (PLA2). It was suggested as an alternative treatment for atherosclerosis through its ability to inhibit PLA2 by binding to its substrate PE. Moreover, Cinnamycin was found to inhibit Herpes simplex virus (HSV-1) activity.

Cinnamycin is a tetracyclic polypeptide antibiotic of 19 amino acids.

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable
• 個人防護裝備: Eyeshields, Gloves, type N95 (US)